Improving Treatment Options for Patients with Double Refractory CLL

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) cell growth depend on B-cell receptor (BCR) signaling and apoptosis resistance.
• Covalent Bruton's tyrosine kinase inhibitors (cBTKis) and venetoclax (BCL2 inhibitor) have transformed CLL/SLL treatment, surpassing chemoimmunotherapy.
• Sequential cBTKi and venetoclax therapy is standard but not curative, leaving a need for treatments in double refractory patients.

Purpose of the Study:

• To review treatment options for double refractory CLL/SLL patients who progressed on cBTKis and venetoclax.
• To discuss emerging therapies and resistance mechanisms in CLL/SLL.
• To highlight the potential for personalized treatment approaches.

Main Methods:

• Literature review focusing on treatment of double refractory CLL/SLL.
• Case study of a double refractory CLL patient used as a basis for discussion.
• Analysis of novel agents including non-covalent BTK inhibitors (ncBTKis), CAR T-cell therapy, bispecific antibodies, and BTK degraders.

Main Results:

• Recent approvals of pirtobrutinib (ncBTKi) and lisocabtagene maraleucel (CAR T-cell) show efficacy in double refractory CLL/SLL.
• Several novel therapies are in clinical development, offering future treatment avenues.
• Understanding resistance mechanisms is key to optimizing treatment strategies.

Conclusions:

• Effective treatment options for double refractory CLL/SLL have improved with recent approvals.
• Ongoing research into novel agents and resistance mechanisms promises further advancements.
• Personalized medicine approaches are crucial for managing complex CLL/SLL cases.